...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN-3694 and Enzalutamide 2b Trial

The clinical work seems to be going quite well for Zenith. Hopefully we get a corporate update soon. Don had said a while ago that he thought a quarterly update would be doable, even a short one addressing the business status would be good. In December he had mentioned that they could be unlocking some significant value in the "near future".  I would like to hear more about any progress there. 

Share
New Message
Please login to post a reply